|
FRG1B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.10410000031536E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.18719999947703E-07 |
| Normal-vs-Stage2 |
4.140500E-03 |
| Normal-vs-Stage3 |
4.63629999947202E-08 |
| Normal-vs-Stage4 |
1.06899999963161E-07 |
| Stage1-vs-Stage2 |
4.221200E-01 |
| Stage1-vs-Stage3 |
7.268000E-02 |
| Stage1-vs-Stage4 |
7.320000E-02 |
| Stage2-vs-Stage3 |
6.958000E-02 |
| Stage2-vs-Stage4 |
5.096100E-02 |
| Stage3-vs-Stage4 |
7.285200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.0496999653119E-09 |
| Normal-vs-AfricanAmerican |
1.211720E-02 |
| Normal-vs-Asian |
1.443600E-04 |
| Caucasian-vs-AfricanAmerican |
2.278800E-01 |
| Caucasian-vs-Asian |
5.173000E-01 |
| AfricanAmerican-vs-Asian |
5.188200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.25669999999178E-05 |
| Normal-vs-Female |
6.19139994828544E-09 |
| Male-vs-Female |
8.027600E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.75090000012979E-07 |
| Normal-vs-Age(41-60Yrs) |
1.36250000004612E-06 |
| Normal-vs-Age(61-80Yrs) |
1.59820000011912E-07 |
| Normal-vs-Age(81-100Yrs) |
1.059180E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.454800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.613600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.387370E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.346400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.259200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.011400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.295400E-03 |
| Classical-VS-Follicular |
3.778400E-01 |
| Classical-VS-Other |
3.327200E-01 |
| Classical-VS-Normal |
3.99759999991645E-07 |
| Tall-VS-Follicular |
5.887600E-02 |
| Tall-VS-Other |
7.005600E-01 |
| Tall-VS-Normal |
3.34890000175392E-08 |
| Follicular-VS-Other |
6.069800E-01 |
| Follicular-VS-Normal |
2.27059999999835E-05 |
| Other-VS-Normal |
1.268400E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.94580000018641E-07 |
| Normal-vs-N1 |
8.1943000163065E-09 |
| N0-vs-N1 |
1.564030E-02 |
|
|
